References
- Hawkins BS, Bird A, Klein R, West SK. Epidemiology of age-related macular degeneration. Mol Vis 1999;5:26
- Klaver CC, Wolfs RC, Vingerling JR, Hofman A, deJong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998;116:653–658
- Vingerling JR, Klaver CC, Hofman A, de Jong PT. Epidemiology of age-related maculopathy. Epidemiol Rev 1995;17:347–360
- Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431
- Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for advanced age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417–1436
- Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013;309:2005–2015
- Bressler NM, Bressler SB, Congdon NG, Ferris FL III, Friedman DS, Klein R, et al. Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003;121:1621–1624
- Charkoudian LD, Gower EW, Solomon SD, Schachat AP, Bressler NM, Bressler SB. Vitamin usage patterns in the prevention of advanced age-related macular degeneration. Ophthalmology 2008;115:1032–1038.e4
- Jampol LM. AREDS - two years later. Arch Ophthalmol 2003;121:1634–1636
- Ng WT, Goggin M. Awareness of and compliance with recommended dietary supplement among age-related macular degeneration patients. Clin Exp Ophthalmol 2006;34:9–14
- Chang CW, Chu G, Hinz BJ, Greve MD. Current use of dietary supplementation in patients with age-related macular degeneration. Can J Ophthalmol 2003;38:27–32
- Hochstetler BS, Scott IU, Kunselman AR, Thompson K, Zerfoss E. Adherence to recommendations of the age-related eye disease study in patients with age-related macular degeneration. Retina 2010;30:1166–1170
- Fahed DC, Ghazi NG, Jabbour NM, Fahed CD, Fahed JC, Salti HI. Impact of AREDS in a developing country 5 years after publication of the study. Eur J Ophthalmol 2011;21:67–72
- Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics associated with medication adherence. Clin Med Res 2013;11:54–65
- Evans JR. Risk factors for age-related macular degeneration. Prog Retin Eye Res 2001;20:227–253
- Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995;102:1450–1460
- Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933–943
- Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995;102:205–210
- Stryker JE, Beck AD, Primo SA, Echt KV, Bundy L, Pretorius GC, et al. An exploratory study of factors influencing glaucoma treatment adherence. J Glaucoma 2010;19:66–72
- Friedman DS, Okeke CO, Jampel HD, Ying GS, Plyler RJ, Jiang Y, et al. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Ophthalmology 2009;116:1097–1105
- Turner P, William C. Informed consent: patients listen and read, but what information do they retain? NZ Med J 2002;115:U218
- Rees G, Chong XL, Cheung CY, Aung T, Friedman DS, Crowston JG, et al. Beliefs and adherence to glaucoma treatment: a comparison of patients from diverse cultures. J Glaucoma 2013 Jan 31. [Epub ahead of print]